Central nervous system involvement in chronic lymphocytic leukemia: a real-world analysis
- 18 November 2025
- journal article
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 67 (2) , 475-479
Abstract
No abstract availableFunding Information
- National Cancer Institute of the National Institutes of Health (K08CA270202)
- Scott Nathan and Laura DeBonis Fund for Clinical Research
This publication has 11 references indexed in Scilit:
- Report of Consensus Panel 2 from the 12th International Workshop on the management of Bing-Neel syndrome in patients with Waldenstrom’s MacroglobulinemiaSeminars in Hematology, 2025
- Venetoclax activity in a patient with central nervous system involvement by chronic lymphocytic leukaemiaThe Lancet Haematology, 2022
- Profound response to venetoclax monotherapy in a patient with BCL-2 positive relapsed multiple myeloma and extramedullary CNS manifestationsLeukemia & Lymphoma, 2022
- Venetoclax: A Novel Therapeutic Agent for CLL with CNS InvolvementCase Reports in Oncology, 2022
- Central nervous system relapse of acute promyelocytic leukemia treated by oral Venetoclax with Azacitidine achieved complete remissionAnnals of Hematology, 2022
- Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design studyThe Lancet, 2020
- Venetoclax penetrates in cerebrospinal fluid and may be effective in chronic lymphocytic leukemia with central nervous system involvementHaematologica, 2019
- Anti-CD19 CAR T Cells in CNS Diffuse Large-B-Cell LymphomaNew England Journal of Medicine, 2017
- Management of central nervous system involvement in chronic lymphocytic leukaemia: a retrospective cohort of 30 patientsBritish Journal of Haematology, 2016
- Prevalence and characteristics of central nervous system involvement by chronic lymphocytic leukemiaHaematologica, 2016